Trends in new drug interactions for pharmaceutical products in Japan

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 6, 2006, Pages 421-427

  Yoshida, Naoko ^a   Yamada, Akito ^a   Mimura, Yasuhiko ^a   Kawakami, Junichi ^a   Adachi, Isao ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Drug information; Drug interaction; Japan; Labour and Welfare; Ministry of Health; Pharmaceutical products; Prescription medicines

Indexed keywords

ACETAZOLAMIDE; ACETOHEXAMIDE; AMITRIPTYLINE; CLOMIPRAMINE; CYCLOSPORIN; CYTOCHROME P450 3A4; EPHEDRINE; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GLIBENCLAMIDE; GLICLAZIDE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; ITRACONAZOLE; METHYLEPHEDRINE; MICONAZOLE; PAROXETINE; PHENOBARBITAL; PIMOZIDE; QUINIDINE; SELEGILINE; SIMVASTATIN; TERFENADINE; THIORIDAZINE; TRIAZOLAM; TROGLITAZONE; UNINDEXED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; JAPAN; MENSTRUATION DISORDER; PRIORITY JOURNAL; PUBLICATION; QT PROLONGATION; RHABDOMYOLYSIS; TACHYCARDIA;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG LABELING; JAPAN; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 33745803852     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1197     Document Type: Article

References (20)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospital patients. JAMA 1998; 279: 1200-1205.
2. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652-1658.
3. Tatro DS. Drug Interaction Facts 2005: Facts and Comparisons. Walters Kluwer Health, Inc.: St. Louis, MO, 2005.
4. Hansten PD, Horn JR. Hansten and Horn's Managing Clinically Important Drug Interactions. Facts and Comparisons. Walters Kluwer Health, Inc.: St. Louis, MO, 2004.
5. Stockley IH. Drug Interactions, 6th edn. Pharmaceutical Press: London, 2002.
6. Langdorf MI, Fox JC, Marwah RS, Montague BJ, Hart MM. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7: 1321-1329.
7. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 1999; 56: 1524-1529.
8. Cavuto NJ, Woosley RL, Sale M. Pharmacies and prevention of potentially fatal drug interactions. JAMA 1996; 275: 1086-1087.
9. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274: 29-34.
10. Hansten PD, Horn JR, Hazlet TK. ORCA: operational classification of drug interaction. J Am Pharm Assoc (Wash) 2001; 41: 161-165.
11. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash) 2001; 41: 200-204.
12. Notification #0109110. Medical Economics Division, Health Insurance Bureau, The Ministry of Health, Labour and Welfare, Japan. 9 July 2004. [in Japanese]
13. Seki A, Kitahara M, Ueno F, Echizen H. Newly approved medicines. In Manual of Therapeutic Agents, Takaku F, Yazaki Y (eds). Igaku-Shoin: Tokyo, 2005; 1853-1885 [in Japanese].
14. Yoshida N, Takagi A, Kitazawa H, Kawakami J, Adachi I. Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli Fructus. Toxicol Appl Pharmacol 2005; 209: 167-173.
15. Aronson JK, Grahame-Smith DG. Clinical pharmacology: adverse drug interactions. Br Med J 1981; 282: 288-291.
16. McInnes GT, Brodie MJ. Drug interactions that matter: a critical reappraisal. Drugs 1988; 36: 83-110.
17. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
18. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gillman AG (eds). McGraw-Hill Publishing: St. Louis, MO, 1996; 3-28.
19. van Grootheest AC, van Puijenbroek EP, de long-van den Berg LTW. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 205-210.
20. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76: 85-96.